Galderma Slumps After FDA Turns Down Botox Rival Relfydess

Galderma Group AG shares slumped the most in more than a year after the US Food and Drug Administration turned down the Swiss dermatology firm’s rival Botox treatment Relfydess.

To respect copyright, we link to the source rather than republishing the full text. Read the complete article on Bloomberg.